Oxford Nanopore Technolo... Share Discussion Threads

[brucie5] 19/7/2024 14:26

Lols. I'm sure you're not the only one!

[steeplejack] 19/7/2024 11:47

Interesting to note that my initial buy-in price remains the uncanny reliable top of the current trading range :)

[apple53] 18/7/2024 10:38

Darn it. Maybe 6th time lucky

[apple53] 18/7/2024 10:07

For a moment I thought You had bought 100k, Seball.....

So this is the fifth attempt to break through 115-116, and given yesterday's higher low it is promising.

[seball] 18/7/2024 09:59

100k shares just bought for above ask.. Bodes well... Buy

[chc15] 18/7/2024 07:48

Bought some at 110 near close yesterday. This has some interesting shareholders, they must be pressing the Co for some action.

[steeplejack] 17/7/2024 10:19

Need to break through 115p.Proved to be a resistance level a month or so back but its building nicely.After such underperformance,its not going to take much to see a sharp recovery all things considered.

[chc15] 17/7/2024 09:51

damn, was looking to buy, new brokers always mean something!

[seball] 17/7/2024 08:27

Break out on large volume. 150p next stop. BUY

[eeza] 16/7/2024 14:44

Large churn today.

[trickydicky1] 16/7/2024 06:26

Why not Cavendish in preparation for a relisting on AIM?

[seball] 16/7/2024 06:05

Sounds like preparation for listing in US. That should put a rocket up the share price.

Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the company delivering a new generation of nanopore-based molecular sensing technology, today announces the appointment of Berenberg as joint corporate broker alongside Citigroup Global Markets Limited and J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove) with immediate effect

[bamboo2] 15/7/2024 18:26

Nanopore sequencing demonstrates identification of antibiotic-resistant pathogens hidden to traditional methods in new study

Rapid and accurate antibiotic resistance profiling with Oxford Nanopore sequencing demonstrates potential for clinical impact.

A new study published in Nature Communications has demonstrated the ability of real-time nanopore sequencing in identifying the antibiotic resistance of pathogens hidden to standard traditional methods, such as MALDI-TOF MS and VITEK 2, showcasing the potential for rapid nanopore sequencing to characterise drug resistant infections in a hospital setting.

Rosemary Sinclair Dokos, SVP for Product and Programme Management at Oxford Nanopore Technologies, said that the study “highlights the potential of real-time genomic technology to significantly enhance our understanding of antibiotic resistance,” adding, “by providing rapid and detailed insights, this technology has the potential to support timely and informed decision-making, and could lead to better outcomes in infectious disease and improved public health strategies."

The research, led by Ela Sauerborn under the supervision of Dr. Lara Urban and her team at Helmholtz Center Munich, was conducted in a research hospital and demonstrates how real-time genomics can offer rapid, precise insights that traditional methods might miss.

Antibiotic resistance is recognised as one of the top ten global health threats, increasing mortality and morbidity due to delayed or inappropriate therapy. The study emphasises the urgent need for rapid and accurate pathogen identification to combat this issue effectively. In terms of speed, the study showcases equivalence of nanopore sequencing to traditional methods. However, the biggest differentiator is that, within a similar timeframe to VITEK 2 and MALDI-TOF MS, real-time genomics uncovered plasmid-encoded resistance genes that these methods missed - identification of which is crucial for timely and appropriate therapy.

This point was demonstrated in a case study by Dr. Urban’s team that focused on a multi-drug resistant Klebsiella pneumoniae infection. This strain of bacteria has developed antibiotic resistance in some cases, and a decision was made to change antibiotic treatment from Meropenem to Ceftazidime-Avibactam (CAZ-AVI), the latter being recommended given the strain’s susceptibility to CAZ-AVI. However, traditional methods were unable to detect that the Klebsiella pneumoniae infection had developed resistance to CAZ-AVI itself.

In a recreation of the case study, Dr. Urban’s team used nanopore sequencing to accurately identify the presence of KPC-14 resistance genes, predicting antibiotic resistance accurately as opposed to established clinical diagnostics. This demonstrated that nanopore sequencing could have unveiled the CAZ-AVI resistance that other methods failed to detect, thereby influencing the therapeutic approach, such as the early administration of alternative antibiotics or combination therapy and potentially leading to positive outcomes. Further, this approach is cost-effective and suitable for global application in every clinical microbiology setting, while the accessibility of the platform enables low- and middle-income settings to adopt real-time genomic tools, particularly where there are barriers to the use of standard diagnostic machinery.

Dr. Lara Urban commented, "The fast, adaptive, and in situ nature of antibiotic resistance profiling by nanopore sequencing would have surpassed current clinical practice in accurately informing clinical management."

The study was conducted in collaboration with esteemed institutions, including the Technical University of Munich, Helmholtz Zentrum München, and the European Molecular Biology Laboratory European Bioinformatics Institute. This partnership underscores the global effort to advance genomic research and combat antibiotic resistance through innovative technology.

For more details, please visit the full study published in Nature Communications.


First author Ela Sauerborn will be discussing this research at the Nanopore Community Meeting 2024: Boston this September

[bamboo2] 08/7/2024 18:54

Nanopore is currently being installed in around 10 NHS hospitals as an extension of the original 2/3yr trial at Guys and St. Thomas' in London.

The workflow has been updated so that a single 'assay' can determine from a single sample, between different bacterial, fungal and virial infections. First reports are available in a little as 30mins.

It is the clinical market that will lead to a massive expansion in turnover.

"We are approaching the holy grail of infectious diseases diagnostics."

Clinicians in Sweden, New Zealand, Australia, France and the US are also working on various forms of ONT based diagnostics.

Plain language summary

Metagenomics is the analysis of genetic material from microbes such as bacteria and viruses in a sample. There are limitations with existing metagenomics methods, such as not being able to detect the full range of microbes present in a sample. This paper introduces an approach that identifies multiple types of microbes. This is accomplished through the mechanical disruption of human cells, which allows for an effective depletion of human genetic material. Our method demonstrates encouraging preliminary results within a 7 h process, achieving good sensitivity for the detection of bacteria and viruses. We demonstrate the identification of relevant microbes in samples from patients with respiratory infections. This technique holds promise for adoption in clinical settings, potentially enhancing our ability to diagnose respiratory infections quickly.

[kooba] 08/7/2024 07:59

The Times: The chief executive of Oxford Nanopore has warned that Britain's most promising companies will be 'snapped up' in takeovers or will move their listings to New York unless the new Labour government accelerates financial reforms begun under the Conservatives.

[ih_828197] 05/7/2024 15:05

Imo they are gonna disrupt ILMN just like AMD disrupted Intel.

[mszmu] 05/7/2024 11:15

rec2204 Jul '24 - 10:06 - 1474 of 1474

Why?

[ih_828197] 04/7/2024 09:06

the tide is turning if earnings and guidance are good this will see 200p in the short term, long term i truly believe ONT is a 100B company in the making, it feels like investing in AMD in 2014

[csalvage] 04/7/2024 08:51

Berenberg cuts Oxford Nanopore price target to 282 (350) pence - 'buy'

[bamboo2] 03/7/2024 15:24

Sequencing for a new generation.

With Apple silicon and Oxford Nanopore, sequencing becomes not just powerful but also more globally accessible...

[eeza] 28/6/2024 09:31

Circling the plughole, again.

[steeplejack] 27/6/2024 16:34

Chunky seller has been overhanging the price by all accounts rather than some prop. trader.Maybe the seller is finished.

[steeplejack] 26/6/2024 12:53

This has got the feel of a second liner being tossed hither and thither by some proprietary book looking to make his daily beer money.By the end of the year,the stock should garner greater respect for the various reasons mentioned previously.

It’s a far cry from those heady floatation days three years back.Another casualty of the ‘irrational exuberance’ that surrounded so many covid plays that benefitted,but were then subsequently plagued, by post covid rating trauma!

“Nanopore, a spin-off from Oxford University whose handheld genome-sequencing devices are being used to track emerging Covid-19 strains, launched with a value of £3.4 billion from shares priced at 425p.

Within an hour, the stock soared to 619.9p lifting its market cap to within a shade of £5 billion - double the implied valuation from a funding round in May.”